Skip to main content

Table 2 Predicted per year benefits of Wolbachia programmes in four sites. Only eligible areas (at least 1000 people per km2) receive treatment. All costs are in 2018 US dollars and are not discounted. Figures in brackets represent 95% uncertainty intervals

From: The cost-effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: a modelling study

 

Committed area

Scale-up scenario

Yogyakarta City

Remaining Yogyakarta SAR

Jakarta

Bali

Baseline cases per year (area wide)

14,488 (2955–47,858)

93,604 (21,527–249,843)

444,528 (97,542–1,189,217)

117,840 (27,862–324,114)

Post Wolbachia cases per year (area wide)

722 (0–30,140)

36,674 (6805–180,567)

127,712 (0–749,850)

62,033 (9810–237,984)

Area-wide percent reduction (%)

94.4 (36.5–100)

59.1 (25.6–69.6)

65.7 (36.7–100)

52.4 (24.2–66.9)

Percent reduction within treated areas

94.4 (36.5–100)

87.2 (37.2–100)

65.7 (36.7–100)

82.8 (37.3–100)

Averted medical costs per year (millions USD)

0.46 (0.14–1.19)

2.16 (0.67–4.70)

12.91 (4.49–25.08)

2.58 (0.82–5.11)

Averted societal costs per year (millions USD)

0.52 (0.21–0.98)

2.36 (1.05–4.28)

14.17 (6.09–24.27)

2.77 (1.23–4.74)